Apogee Therapeutics (APGE) Preferred Stock Liabilities (2022 - 2023)
Apogee Therapeutics (APGE) reported Preferred Stock Liabilities of $148.5 million for Q3 2023, up 1717.35% year-over-year from $8.2 million in Q3 2022, and little changed on a QoQ basis from $148.5 million in Q2 2023.
Apogee Therapeutics (APGE) has 2 years of Preferred Stock Liabilities data on file, last reported at $148.5 million in Q3 2023.
- Quarterly Preferred Stock Liabilities rose 1717.35% year-over-year to $148.5 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $148.5 million (up 1717.35% YoY) and the FY2022 annual result came in at $29.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $148.5 million in Q3 2023 per APGE's latest filing, from $148.5 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $148.5 million in Q2 2023 and bottomed at $3.8 million in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Apogee Therapeutics | 5.53 Bn | 4.47 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 148.50 Mn |
| Jun 30, 2023 | 148.50 Mn |
| Mar 31, 2023 | 28.97 Mn |
| Dec 31, 2022 | 28.97 Mn |
| Sep 30, 2022 | 8.17 Mn |
| Jun 30, 2022 | 3.77 Mn |